 Home > Medical News > Latest Medical News > Longeveron shares soar 105% after Phase I results of new Alzheimer's drug

Longeveron shares soar 105% after Phase I results of new Alzheimer's drug

 Last Update: 2022-04-19
 Source: Internet
 Author: User

Tags

domains life

data analysis process

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Cube Info

Author: Pickup

On March 31, Longeveron announced that the journal Alzheimer's & Dementia® published results from a Phase I trial in patients with mild Alzheimer's disease (AD)

Affected by the news, the company's shares rose 105%

Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell (MSC) product

The article, "Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer's disease," details the results of the Lomecel-B study

The study met its primary endpoint - safety

Other exploratory findings include:

The Mini-Cognitive Status Evaluation Scale (MMSE), which is used to assess cognitive status, showed a slower decline in scores in the low-dose Lomecel-B group compared with the placebo group

Based on the findings, Longeveron opened a new, larger, double-blind, randomized, placebo-controlled Phase II study to evaluate the effects of single and multiple doses of Lomecel-B in the treatment of mild AD

In addition to being used to treat AD, Lomecel-B is also being developed for the treatment of frail aging, hypoplastic left heart syndrome, and acute respiratory distress syndrome caused by COVID-19

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.